ST. LOUIS, MO--(Marketwired - January 13, 2014) -
Mobius Therapeutics has received approval for Mitosol® (mitomycin for solution) Kit for Ophthalmic Use
reimbursement in 2014. After reviewing the final OPPS/ASC rule from the Center for Medicare and Medicaid Services (CMS) regarding 2014 reimbursement, Mitosol®
will receive a separate reimbursement at 106 percent of the Average Sales Price (ASP).
"As the convenience, containment, and consistency aspects of Mitosol® remain unprecedented, this economic assurance allows providers to know their concerns regarding ophthalmic mitomycin are answered by a single, FDA approved product," said Ed Timm, President and CEO of Mobius Therapeutics. "We know all payors look to Medicare's expertise, and we expect to continue to see broad coverage of Mitosol®. We applaud CMS in assuring existing and new Mitosol® patients and providers economic security. Access to Mitosol® will meet their needs, both clinical and financial, regardless of the site of service," said Timm.
About Mobius Therapeutics, LLC:
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration. Please see full prescribing information at www.MobiusTherapeutics.com Mobius is housed within the Center for Emerging Technologies in St. Louis, Missouri.